Just speculating here but if I was to pick 1 of them as being the most successful it would be MANF. JP Morgan has recently raised the price target of leading Calcium Channel Blocker manufacturers, the ones known to block inflammation. We should all know from doing our DD that Dr. Urano is studying Verapamil as a drug against Wolfram and Diabetes as it reduces inflammation/TXNIP. Along with a helper boost from MANF this combination, I believe we will be a winner.
Verapamil produced by Mylan Feb. 28,2014 Mylan (NASDAQ:MYL) had its price target upped by JPMorgan Chase from $50 to $65
News 
Market Data 
Discover 
AI
